Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of$ 0.44. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this epilepsy drug developer would post a loss of$ 0.59 per share when it actually produced a loss of $0.60, delivering a surprise of -1.69%.Over the last four quarters, t ...